ENHERTU® Improves Disease-Free Survival in Breast Cancer Trial
Positive topline results from a planned interim analysis of the DESTINY-Breast05 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in...